Acadia: Don't expect Nuplazid NDA until 1Q 2015
This article was originally published in Scrip
Not only did Acadia Pharmaceuticals disappoint investors by missing the mark in reporting the firm's quarterly earnings, but the company disclosed its new drug application (NDA) for its investigational Parkinson's disease psychosis drug Nuplazid (pimavanserin) would not be coming this year, and would need to wait until the first quarter of 2015.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.